Good morning :)
Place Order
Add to Watchlist

SMS Lifesciences India Ltd

SMSLIFE

SMS Lifesciences India Ltd

SMSLIFE
Health CarePharmaceuticals
SmallcapWith a market cap of ₹363 cr, stock is ranked 2,075
High RiskStock is 4.37x as volatile as Nifty
1,201.500.12% (-1.40)
1,201.500.12% (-1.40)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Health CarePharmaceuticals
SmallcapWith a market cap of ₹363 cr, stock is ranked 2,075
High RiskStock is 4.37x as volatile as Nifty

How to use scorecard? Learn more

Health CarePharmaceuticals
SmallcapWith a market cap of ₹363 cr, stock is ranked 2,075
High RiskStock is 4.37x as volatile as Nifty

Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
16.591.880.12%
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
51.496.670.52%

Forecast & Ratings

Detailed Forecast 
Forecast data is currently unavailable for this stock

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

SMS Lifesciences India is engaged in the business of manufacturing, buying, selling, offering consultancy, importing and exporting, acting as commission agents and generally dealing with of all types of organic and inorganic chemicals,pharmaceuticals

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Forecasts

Price

Revenue

Earnings

Income

Balance Sheet

Cash Flow

Income Statement

Industry refers to the sub-sector this company belongs to.

Lower than Industry Revenue Growth

A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of -4.02%, vs industry avg of 9.04%

Decreasing Market Share

Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share decreased from 0.17% to 0.08%

Lower than Industry Net Income

Net income is equal to net earnings (profit) less expenses. This number is an important measure of how profitable the company is

Over the last 5 years, net income has grown at a yearly rate of -12.6%, vs industry avg of 15.28%

Loading...

Financial YearFY 2019FY 2020FY 2021FY 2022FY 2023FY 2024TTM
Total Revenue380.36263.06267.37364.50320.98309.79338.48
Raw Materialssubtract268.79147.04135.17204.47171.33150.19287.55
Power & Fuel Costsubtract25.9320.4821.5630.0229.2830.46
Employee Costsubtract23.1126.5630.6639.9043.4349.27
Selling & Administrative Expensessubtract11.989.2812.2813.7712.5214.20
Operating & Other expensessubtract13.2832.0235.6827.3730.1830.62
Depreciation/Amortizationsubtract6.387.867.8610.0110.7914.9414.95
Interest & Other Itemssubtract5.515.154.606.236.8710.269.72
Taxes & Other Itemssubtract7.544.496.027.415.130.754.37
EPS59.0133.6744.7983.7537.8730.1072.40
DPS1.500.001.501.501.501.501.50
Payout ratio0.030.000.030.020.040.050.02

Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange

Peers & Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
SMS Lifesciences India Ltd39.921.880.12%
Sun Pharmaceutical Industries Ltd46.136.580.73%
Cipla Ltd29.214.490.87%
Mankind Pharma Ltd62.9112.57

Price Comparison

Compare SMSLIFE with any stock or ETF
Compare SMSLIFE with any stock or ETF
SMSLIFE
Loading...

Shareholdings

Promoter Holdings Trend

Total Promoter Holding

Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding

Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Institutional Holdings Trend

Total Retail Holding

Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Foreign Institutional Holding

Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding71.41%0.00%0.00%0.02%28.57%

Dec 2023

Mar 2024

Jun 2024

Sep 2024

Shareholding History

JunSepDec '23MarJunSep0.00%0.00%0.00%0.00%0.01%0.02%

Insider Trades & Bulk Deals

Loading...

smallcases

Looks like this stock is not in any smallcase yet.

Events

Dividend Trend

No dividend trend available

Dividends

Corp. Actions

Announcements

Legal Orders

Upcoming Dividends

No upcoming dividends are available

Past Dividends

Cash Dividend

Ex DateEx DateSep 23, 2024

Final
Final | Div/Share: ₹1.50

Dividend/Share

1.50

Ex DateEx Date

Sep 23, 2024

Cash Dividend

Ex DateEx DateSep 22, 2023

Final
Final | Div/Share: ₹1.50

Dividend/Share

1.50

Ex DateEx Date

Sep 22, 2023

Cash Dividend

Ex DateEx DateSep 22, 2022

Final
Final | Div/Share: ₹1.50

Dividend/Share

1.50

Ex DateEx Date

Sep 22, 2022

Cash Dividend

Ex DateEx DateSep 20, 2021

Final
Final | Div/Share: ₹1.50

Dividend/Share

1.50

Ex DateEx Date

Sep 20, 2021

Cash Dividend

Ex DateEx DateSep 19, 2019

Final
Final | Div/Share: ₹1.50

Dividend/Share

1.50

Ex DateEx Date

Sep 19, 2019

News & Opinions
Earnings
SMS Lifesciences India consolidated net profit rises 586.76% in the September 2024 quarter

Net profit of SMS Lifesciences India rose 586.76% to Rs 4.67 crore in the quarter ended September 2024 as against Rs 0.68 crore during the previous quarter ended September 2023. Sales rose 13.28% to Rs 78.46 crore in the quarter ended September 2024 as against Rs 69.26 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales78.4669.26 13 OPM %10.9111.45 - PBDT8.475.39 57 PBT4.701.66 183 NP4.670.68 587 Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
SMS LifeSciences India to conduct board meeting

SMS LifeSciences India will hold a meeting of the Board of Directors of the Company on 13 November 2024Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
SMS LifeSciences India AGM scheduled

SMS LifeSciences India announced that the 18th Annual General Meeting (AGM) of the company will be held on 30 September 2024.Powered by Capital Market - Live

4 months agoCapital Market - Live
Earnings
SMS Lifesciences India reports consolidated net profit of Rs 7.00 crore in the June 2024 quarter

Net profit of SMS Lifesciences India reported to Rs 7.00 crore in the quarter ended June 2024 as against net loss of Rs 1.80 crore during the previous quarter ended June 2023. Sales rose 23.98% to Rs 92.55 crore in the quarter ended June 2024 as against Rs 74.65 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales92.5574.65 24 OPM %17.593.39 - PBDT14.320.97 1376 PBT10.64-2.73 LP NP7.00-1.80 LP Powered by Capital Market - Live

4 months agoCapital Market - Live
Corporate
SMS LifeSciences India schedules board meeting

SMS LifeSciences India will hold a meeting of the Board of Directors of the Company on 9 August 2024.Powered by Capital Market - Live

4 months agoCapital Market - Live

SMS Lifesciences India consolidated net profit rises 59.80% in the March 2022 quarter

2 years agoBusiness Standard

SMS Lifesciences India divests 10% stake of wholly-owned subsidiary, Mahi Drugs

2 years agoBusiness Standard

Sandur Manganese & Iron Ores Ltd leads gainers in ‘B’ group

2 years agoBusiness Standard

SMS Lifesciences shares jump 20% after USFDA issues zero observation for Telangana unit

2 years agoMoneycontrol

SMS Lifesciences soars after API Facility completes USFDA Inspection with No Observations

2 years agoBusiness Standard